| Market Cap | 441.55B | P/E | 34.46 | EPS this Y | 1.00% | Ern Qtrly Grth | - |
| Income | 19.17B | Forward P/E | 16.54 | EPS next Y | 3.20% | 50D Avg Chg | 5.00% |
| Sales | 85.65B | PEG | 2.93 | EPS past 5Y | 5.55% | 200D Avg Chg | 3.00% |
| Dividend | 3.00% | Price/Book | 5.87 | EPS next 5Y | 4.93% | 52W High Chg | -6.00% |
| Recommedations | 2.40 | Quick Ratio | - | Shares Outstanding | 2.41B | 52W Low Chg | 13.00% |
| Insider Own | 0.09% | ROA | - | Shares Float | 2.40B | Beta | 0.53 |
| Inst Own | 71.21% | ROE | - | Shares Shorted/Prior | 15.94M/14.85M | Price | 169.91 |
| Gross Margin | 69.33% | Profit Margin | 47.37% | Avg. Volume | 7,935,243 | Target Price | 164.19 |
| Oper. Margin | 28.80% | Earnings Date | Jul 17 | Volume | 14,213,937 | Change | 0.60% |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
| HSBC | Buy | Apr 18, 24 |
| RBC Capital | Outperform | Apr 17, 24 |
| Cantor Fitzgerald | Overweight | Apr 17, 24 |
| Morgan Stanley | Equal-Weight | Apr 17, 24 |
| B of A Securities | Neutral | Apr 17, 24 |
| Cantor Fitzgerald | Overweight | Apr 15, 24 |
| Cantor Fitzgerald | Overweight | Mar 13, 24 |
| RBC Capital | Outperform | Feb 28, 24 |
| Cantor Fitzgerald | Overweight | Feb 20, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fasolo Peter | Exec VP, Chief HR Of.. Exec VP, Chief HR Officer | Jul 25 | Sell | 170.3249 | 20,000 | 3,406,498 | 102,696 | 07/27/23 |
| Hait William | See Remarks See Remarks | Jul 26 | Sell | 172 | 14,698 | 2,528,056 | 87,747 | 07/27/23 |
| Hait William | See Remarks See Remarks | Jul 26 | Option | 90.44 | 14,698 | 1,329,287 | 102,445 | 07/27/23 |
| Swanson James D. | See Remarks See Remarks | Mar 06 | Sell | 154.6600 | 1,062 | 164,199 | 9,215 | 03/08/23 |
| McEvoy Ashley | EVP, WW Chair, MedTe.. EVP, WW Chair, MedTech | Nov 30 | Option | 72.54 | 73,323 | 5,318,850 | 115,136 | 12/02/22 |
| McEvoy Ashley | EVP, WW Chair, MedTe.. EVP, WW Chair, MedTech | Nov 30 | Sell | 175.77 | 73,323 | 12,887,984 | 41,813 | 12/02/22 |
| Wengel Kathryn E | EVP, Chief GSC Offic.. EVP, Chief GSC Officer | Nov 09 | Option | 72.54 | 16,410 | 1,190,381 | 87,721 | 11/10/22 |
| Wengel Kathryn E | EVP, Chief GSC Offic.. EVP, Chief GSC Officer | Nov 09 | Sell | 173.42 | 16,410 | 2,845,822 | 71,311 | 11/10/22 |
| Mongon Thibaut | Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer | Nov 07 | Option | 108.77 | 17,043 | 1,853,767 | 57,176 | 11/09/22 |
| Mongon Thibaut | Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer | Nov 04 | Sell | 171.18 | 35,246 | 6,033,410 | 40,133 | 11/08/22 |
| Mongon Thibaut | Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer | Nov 04 | Option | 130.73 | 35,246 | 4,607,710 | 75,379 | 11/08/22 |
| Wengel Kathryn E | EVP, Chief GSC Offic.. EVP, Chief GSC Officer | Jun 10 | Option | 72.54 | 40,000 | 2,901,600 | 111,311 | 06/14/22 |
| Wengel Kathryn E | EVP, Chief GSC Offic.. EVP, Chief GSC Officer | Jun 10 | Sell | 173 | 40,000 | 6,920,000 | 71,311 | 06/14/22 |
| Decker Robert J | Controller, CAO Controller, CAO | May 26 | Option | 72.54 | 8,462 | 613,833 | 23,935 | 05/31/22 |
| Decker Robert J | Controller, CAO Controller, CAO | May 26 | Sell | 180 | 8,462 | 1,523,160 | 15,473 | 05/31/22 |
| Hait William | See Remarks See Remarks | Apr 21 | Option | 90.44 | 29,699 | 2,685,978 | 109,935 | 04/25/22 |
| Hait William | See Remarks See Remarks | Apr 21 | Sell | 183.58 | 29,699 | 5,452,142 | 80,236 | 04/25/22 |
| Gorsky Alex | Director Director | Jan 14 | Option | 65.37 | 231,951 | 15,162,637 | 695,601 | 01/19/22 |
| Duato Joaquin | CEO CEO | Jan 14 | Option | 65.37 | 84,423 | 5,518,732 | 280,475 | 01/19/22 |
| Sneed Michael E | EVP, Global Corp Aff.. EVP, Global Corp Aff & COO | Dec 10 | Option | 62.2 | 54,662 | 3,399,976 | 110,741 | 12/10/20 |
| Sneed Michael E | EVP, Global Corp Aff.. EVP, Global Corp Aff & COO | Dec 10 | Sell | 152.93 | 54,662 | 8,359,460 | 56,079 | 12/10/20 |